Deltex Medical Regulatory News (DEMG)

25 Jul 2007 11:30

Deltex Medical Group PLC25 July 2007 Deltex Medical Group plc Use of CardioQTM recommended for all London hospitals 25 July 2007 - Deltex Medical Group plc ("Deltex Medical" or "Company"), theUK's leading haemodynamic monitoring company, notes that a major report into thefuture of healthcare in London has recommended increased use of oesophagealDoppler monitoring. The Planned Care Clinical Working Group was established to report into theHealthcare for London Review. This review was led by Sir Ara Darzi, who wasrecently appointed a minister at the Department of Health, with responsibilityfor conducting the national NHS Next Stage review. The report draws on treatment methodologies established in Australia andrecommends (recommendation 10) that these are established across London: "When integrating the Melbourne model of treatment into a care package withother (cheap) evidence-based interventions (such as use of perioperative Dopplerstudies and early feeding/topping up of fluids) quality of care is furtherimproved and length of stay reduced. Thus, seven randomised trials have shownsimple use of cheap Doppler technology to reduce length of stay consistently bytwo to three days in elective intra-abdominal surgery. It is recommended thatphysician and intensive care management be better integrated with surgicalpractice, and that appropriate evidence-based care bundles be rapidlyestablished and implemented London-wide." The full report can be viewed at http://www.healthcareforlondon.nhs.uk/framework_for_action.asp under the link to 'Planned Care'. Commenting on the report's recommendation, Deltex Medical's Chief Executive,Andy Hill said: "The London Planned Care report puts wide-scale use of the CardioQ exactly whereit should be: at the heart of improving healthcare quality and efficiency." For further information, please contact:- Deltex Medical Group plc 01243 774 837Nigel Keen, Chairman njk@deltexmedical.comAndy Hill, Chief Executive ahill@deltexmedical.comEwan Phillips, Finance Director eap@deltexmedical.com Gavin Anderson & Company 0207 554 1400Deborah Walter dwalter@gavinanderson.co.ukRobert Speed rspeed@gavinanderson.co.uk Charles Stanley Securities 020 7149 6457Philip Davies philip.davies@csysecurities.comRussell Cook russell.cook@csysecurities.com Notes for Editors Deltex Medical manufactures and markets the CardioQTM monitor, which usesdisposable ultra-sound probes inserted into the oesophagus to determine theamount of blood being pumped around the body - 'circulating blood volume'.Reduced circulating blood volume is known as hypovolaemia, which leads toinsufficient oxygen being delivered to the organs. This causes medicalcomplications including peripheral and major organ failure which can lead todeath. Hypovolaemia, which is akin to severe dehydration, affects virtuallyevery patient having surgery because of the combined effects of pre-operativestarvation, the impact of the anaesthetic agents and trauma from the surgeryitself. Using fluids and drugs, guided by the CardioQ, to optimise the amount ofcirculating blood significantly reduces post-operative complications allowingpatients to make a faster, more complete recovery and return home earlier. The CardioQ incorporates the Company's proprietary software and a smalldiameter, easy-to-use, minimally invasive, disposable oesophageal probe that isused for transmitting and receiving an ultra-sound signal. By using thistechnology, the CardioQ provides clinicians with the ability to haemodynamicallyoptimise critically ill patients and those undergoing routine moderate to majorsurgery through the controlled administration of fluid and drugs. Haemodynamicoptimisation has been scientifically proven to improve the speed and quality ofpatient recovery and reduce hospital stay. There are already over 1,250 CardioQs currently in use in hospitals worldwideand distribution arrangements are in place in over 30 countries. In addition,there are currently more than 90 clinical publications on the use of the CardioQwhich have repeatedly:- •Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works •Proved that the CardioQ works in a wide range of surgical procedures •Demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients. The SupraQTM is an entirely non-invasive device which uses an ultrasound probeheld at the base of the patient's neck to track the flow of blood in the aorta;it presents the same data as the CardioQ in a similar format and is used fortaking snapshots or monitoring over short periods. This information is provided by RNS The company news service from the London Stock Exchange